Is Viking Therapeutics a Top Takeover Target?

Viking Therapeutics (NASDAQ: VKTX) increasingly looks like an acquisition candidate in biotech. But why?It's because large pharmaceutical companies are desperate to secure obesity drug exposure, and Viking controls one of the more advanced independent GLP-1/GIP programs still available.Its lead obesity candidate, VK2735, is currently being developed in both injectable and oral formulations. The company's Phase 3 VANQUISH obesity studies are already fully enrolled, while management expects to initiate Phase 3 trials for the oral tablet later this year. Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool